Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma

Sandra Iurescia, Daniela Fioretti, Vito Michele Fazio, Monica Rinaldi

Research output: Contribution to journalArticle

Abstract

Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a cancer vaccine. It has been theorized that effective cancer vaccines can be developed using the minimum essential subset of T cell and B cell epitopes that comprise the 'immunome', the universe of neoplasm-derived peptides that interface with B and T cells of the host immune system. Idiotypic antigenic determinants of a B-cell lymphoma lie within the hypervariable regions and mainly within the complementarity-determining regions (CDR)s 3. Thus, the CDR3s are considered a "hot spot" of particular interest for construction of subunit vaccines. DNA vaccines, whose safety and tolerability are substantiated in completed and ongoing clinical trials, have emerged as a novel lymphoma vaccine formulation for antigen-specific immunotherapy. The molecular precision tools offered by gene-based vaccines allow to explore the use of CDR3 sequence as an antilymphoma vaccine.

Original languageEnglish
Pages (from-to)414-422
Number of pages9
JournalCurrent Gene Therapy
Volume11
Issue number5
Publication statusPublished - Oct 2011

Fingerprint

Cancer Vaccines
DNA Vaccines
B-Cell Lymphoma
Epitopes
Vaccines
Neoplasm Antigens
Immunotherapy
Immunoglobulin Idiotypes
Complementarity Determining Regions
B-Lymphocyte Epitopes
Subunit Vaccines
T-Lymphocyte Subsets
Immune System
Lymphoma
B-Lymphocytes
Clinical Trials
T-Lymphocytes
Safety
Antigens
Peptides

Keywords

  • Cancer vaccines
  • Dna vaccines
  • Immunotherapy
  • Personalised medicine
  • Preclinical models
  • References
  • Targeted cancer therapies
  • Tumor-specific antigens

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery

Cite this

Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma. / Iurescia, Sandra; Fioretti, Daniela; Fazio, Vito Michele; Rinaldi, Monica.

In: Current Gene Therapy, Vol. 11, No. 5, 10.2011, p. 414-422.

Research output: Contribution to journalArticle

Iurescia, Sandra ; Fioretti, Daniela ; Fazio, Vito Michele ; Rinaldi, Monica. / Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma. In: Current Gene Therapy. 2011 ; Vol. 11, No. 5. pp. 414-422.
@article{5e75e949c5f94916b2c55cb32ff56156,
title = "Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma",
abstract = "Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a cancer vaccine. It has been theorized that effective cancer vaccines can be developed using the minimum essential subset of T cell and B cell epitopes that comprise the 'immunome', the universe of neoplasm-derived peptides that interface with B and T cells of the host immune system. Idiotypic antigenic determinants of a B-cell lymphoma lie within the hypervariable regions and mainly within the complementarity-determining regions (CDR)s 3. Thus, the CDR3s are considered a {"}hot spot{"} of particular interest for construction of subunit vaccines. DNA vaccines, whose safety and tolerability are substantiated in completed and ongoing clinical trials, have emerged as a novel lymphoma vaccine formulation for antigen-specific immunotherapy. The molecular precision tools offered by gene-based vaccines allow to explore the use of CDR3 sequence as an antilymphoma vaccine.",
keywords = "Cancer vaccines, Dna vaccines, Immunotherapy, Personalised medicine, Preclinical models, References, Targeted cancer therapies, Tumor-specific antigens",
author = "Sandra Iurescia and Daniela Fioretti and Fazio, {Vito Michele} and Monica Rinaldi",
year = "2011",
month = "10",
language = "English",
volume = "11",
pages = "414--422",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Design and pre-clinical development of epitope-based DNA vaccines against B-cell lymphoma

AU - Iurescia, Sandra

AU - Fioretti, Daniela

AU - Fazio, Vito Michele

AU - Rinaldi, Monica

PY - 2011/10

Y1 - 2011/10

N2 - Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a cancer vaccine. It has been theorized that effective cancer vaccines can be developed using the minimum essential subset of T cell and B cell epitopes that comprise the 'immunome', the universe of neoplasm-derived peptides that interface with B and T cells of the host immune system. Idiotypic antigenic determinants of a B-cell lymphoma lie within the hypervariable regions and mainly within the complementarity-determining regions (CDR)s 3. Thus, the CDR3s are considered a "hot spot" of particular interest for construction of subunit vaccines. DNA vaccines, whose safety and tolerability are substantiated in completed and ongoing clinical trials, have emerged as a novel lymphoma vaccine formulation for antigen-specific immunotherapy. The molecular precision tools offered by gene-based vaccines allow to explore the use of CDR3 sequence as an antilymphoma vaccine.

AB - Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a cancer vaccine. It has been theorized that effective cancer vaccines can be developed using the minimum essential subset of T cell and B cell epitopes that comprise the 'immunome', the universe of neoplasm-derived peptides that interface with B and T cells of the host immune system. Idiotypic antigenic determinants of a B-cell lymphoma lie within the hypervariable regions and mainly within the complementarity-determining regions (CDR)s 3. Thus, the CDR3s are considered a "hot spot" of particular interest for construction of subunit vaccines. DNA vaccines, whose safety and tolerability are substantiated in completed and ongoing clinical trials, have emerged as a novel lymphoma vaccine formulation for antigen-specific immunotherapy. The molecular precision tools offered by gene-based vaccines allow to explore the use of CDR3 sequence as an antilymphoma vaccine.

KW - Cancer vaccines

KW - Dna vaccines

KW - Immunotherapy

KW - Personalised medicine

KW - Preclinical models

KW - References

KW - Targeted cancer therapies

KW - Tumor-specific antigens

UR - http://www.scopus.com/inward/record.url?scp=80053525294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053525294&partnerID=8YFLogxK

M3 - Article

C2 - 21711228

AN - SCOPUS:80053525294

VL - 11

SP - 414

EP - 422

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 5

ER -